Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 3/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12351438 | 0.98 | CA1 (0.52) | CA1L3MBTL1ACE2MEN1KMT2A | |
| SCHEMBL20445091 | 0.95 | L3MBTL1 (0.53) | CA1L3MBTL1ACE2MEN1KMT2A | |
| SCHEMBL27650965 | 0.95 | L3MBTL1 (0.53) | CA1L3MBTL1ACE2MEN1KMT2A | |
| SCHEMBL12352198 | 0.94 | L3MBTL1 (0.53) | CA1L3MBTL1ACE2MEN1KMT2A | |
| SCHEMBL19778874 | 0.92 | L3MBTL1 (0.46) | CA1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL26753717 | 0.89 | L3MBTL1 (0.50) | CA1L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL16417923 | 0.88 | HSD17B10 (0.48) | CA1L3MBTL1ACE2MEN1KMT2A | |
| SCHEMBL19364611 | 0.88 | HSD17B10 (0.48) | CA1L3MBTL1ACE2MEN1KMT2A | |
| SCHEMBL16417928 | 0.86 | CYP3A4 (0.54) | CA1ACE2MEN1KMT2A | |
| SCHEMBL21730562 | 0.86 | CA1 (0.44) | CA1L3MBTL1ACE2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | CA1 1574/4885L3MBTL1 4750/4885ACE2 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.